Dinaciclib

DB12021InvestigationalSmall molecule

Dinaciclib has been used in trials studying the treatment of rrMM, rrCLL, rrDLBCL, Solid Tumors, and Solid Neoplasm, among others.

Mechanism: Pharmacologically active on Cyclin-dependent kinase 5, Cyclin-dependent kinase 1, and Cyclin-dependent kinase 2
Curator reviewed
Formula / weight: C₂₁H₂₈N₆O₂ · 396.495 g/mol (avg)
Code names: MK-7965 · SCH-727965

Resolves to

Compound

Structure

InChIKeyPIMQWRZWLQKKBJ-SFHVURJKSA-NSMILESCCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N1CCCC[C@H]1CCO

Targets

What you can answer from here — as of June 15, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

18Clinical trialsPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dinaciclib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.